Literature DB >> 17938380

Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension.

Ahmed A Elmarakby1, Jeffrey E Quigley, Jeffrey J Olearczyk, Aarthi Sridhar, Anthony K Cook, Edward W Inscho, David M Pollock, John D Imig.   

Abstract

The present study was designed to determine whether chemokine receptor 2b (CCR2b) contributes to the development of renal injury in salt-sensitive angiotensin II (ANG) hypertension. Rats were infused with ANG and fed a high-salt diet (HS) for 14 days. Rats were divided into 4 groups: HS; HS administered the CCR2b antagonist, RS102895; Ang/HS hypertensive; and Ang/HS hypertensive administered RS102895. CCR2b inhibition slowed the progression of blood pressure elevation during the first week of ANG/HS hypertension; however, it did not alter blood pressure in the HS group. At 2 weeks, arterial pressure was not significantly different between ANG/HS and ANG/HS hypertensive rats administered RS102895. Renal cortical nuclear factor kappaB activity increased in ANG/HS hypertension compared with the HS group (0.11+/-0.006 versus 0.08+/-0.003 ng of activated nuclear factor kappaB per microgram of protein), and RS102895 treatment lowered nuclear factor kappaB activity in ANG/HS hypertension (0.08+/-0.005 ng of activated nuclear factor kappaB per microgram of protein). Renal tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression increased, and Cyp2c23 expression decreased in ANG/HS hypertension compared with the HS group, and CCR2b inhibition reduced tumor necrosis factor-alpha and intercellular adhesion molecule-1 and increased Cyp2c23 expression. Histological immunostaining revealed increased renal monocyte and macrophage infiltration in ANG/HS hypertensive rats with decreased infiltration in rats receiving RS102895 treatment. Albuminuria and cortical collagen staining also increased in ANG/HS hypertensive rats, and RS102895 treatment lowered these effects. Afferent arteriolar autoregulatory responses to increasing renal perfusion pressure were blunted in ANG/HS hypertension, and RS102895 treatment improved this response. These data suggest that CCR2b inhibition protects the kidney in hypertension by reducing inflammation and delaying the progression of hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938380      PMCID: PMC2491337          DOI: 10.1161/HYPERTENSIONAHA.107.098806

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  42 in total

1.  CCR2 modulates inflammatory and metabolic effects of high-fat feeding.

Authors:  Stuart P Weisberg; Deborah Hunter; Reid Huber; Jacob Lemieux; Sarah Slaymaker; Kris Vaddi; Israel Charo; Rudolph L Leibel; Anthony W Ferrante
Journal:  J Clin Invest       Date:  2005-12-08       Impact factor: 14.808

2.  Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats.

Authors:  Bernardo Rodríguez-Iturbe; Atilio Ferrebuz; Valentina Vanegas; Yasmir Quiroz; Sergio Mezzano; Nosratola D Vaziri
Journal:  J Pharmacol Exp Ther       Date:  2005-06-10       Impact factor: 4.030

3.  Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism.

Authors:  P Kessler; R Popp; R Busse; V B Schini-Kerth
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

4.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice.

Authors:  L Gu; Y Okada; S K Clinton; C Gerard; G K Sukhova; P Libby; B J Rollins
Journal:  Mol Cell       Date:  1998-08       Impact factor: 17.970

5.  Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-alpha.

Authors:  Yoshihiro Higuchi; Tung O Chan; Maria A Brown; Jin Zhang; Brent R DeGeorge; Hajime Funakoshi; Gregory Gibson; Charles F McTiernan; Toru Kubota; W Keith Jones; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-30       Impact factor: 4.733

6.  Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats.

Authors:  Q Capers; R W Alexander; P Lou; H De Leon; J N Wilcox; N Ishizaka; A B Howard; W R Taylor
Journal:  Hypertension       Date:  1997-12       Impact factor: 10.190

7.  Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone.

Authors:  Gabriella Gruden; Giorgia Setti; Anthea Hayward; David Sugden; Sara Duggan; Davina Burt; Robin E Buckingham; Luigi Gnudi; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2005-01-26       Impact factor: 10.121

8.  TGF-beta impairs renal autoregulation via generation of ROS.

Authors:  Kumar Sharma; Anthony Cook; Matt Smith; Cathryn Valancius; Edward W Inscho
Journal:  Am J Physiol Renal Physiol       Date:  2005-01-11

9.  Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes.

Authors:  Y Jiang; D I Beller; G Frendl; D T Graves
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

10.  Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment.

Authors:  G Grandaliano; L Gesualdo; E Ranieri; R Monno; V Montinaro; F Marra; F P Schena
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

View more
  47 in total

1.  Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Mohammed Al-Shabrawey; Mong-Heng Wang; Krishna Rao Maddipati; John D Imig
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-10       Impact factor: 3.619

2.  Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis.

Authors:  Maki Urushihara; Naro Ohashi; Kayoko Miyata; Ryousuke Satou; Omar W Acres; Hiroyuki Kobori
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 3.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 4.  Interactions Between the Immune and the Renin-Angiotensin Systems in Hypertension.

Authors:  Nathan P Rudemiller; Steven D Crowley
Journal:  Hypertension       Date:  2016-06-27       Impact factor: 10.190

5.  Renal denervation and CD161a immune ablation prevent cholinergic hypertension and renal sodium retention.

Authors:  Nandita Raikwar; Cameron Braverman; Peter M Snyder; Robert A Fenton; David K Meyerholz; Francois M Abboud; Sailesh C Harwani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

6.  Inhibition of cyclooxygenase-2 in hematopoietic cells results in salt-sensitive hypertension.

Authors:  Ming-Zhi Zhang; Bing Yao; Yinqiu Wang; Shilin Yang; Suwan Wang; Xiaofeng Fan; Raymond C Harris
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

Review 7.  The role of chemokines in hypertension and consequent target organ damage.

Authors:  Nathan P Rudemiller; Steven D Crowley
Journal:  Pharmacol Res       Date:  2017-03-06       Impact factor: 7.658

Review 8.  The immunological basis of hypertension.

Authors:  Bernardo Rodríguez-Iturbe; Héctor Pons; Yasmir Quiroz; Richard J Johnson
Journal:  Am J Hypertens       Date:  2014-08-23       Impact factor: 2.689

Review 9.  Innate immunity in hypertension.

Authors:  Muhammad Oneeb Rehman Mian; Pierre Paradis; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 10.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.